busulfan has been researched along with Thalassemias in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We prospectively studied the pharmacokinetics (PK) and clinical outcomes of intravenous busulfan (Bu) in 71 children with preexisting liver damage who underwent hematopoietic stem cell transplantation for thalassemia." | 9.14 | Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. ( Andreani, M; Bernardini, S; Casella, M; Federici, G; Formosa, A; Gaziev, J; Gravina, P; Isgrò, A; Lucarelli, G; Marziali, M; Mozzi, AF; Nguyen, L; Perrone Donnorso, M; Puozzo, C; Simone, MD; Sodani, P; Testi, M, 2010) |
| "In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600 mg/m2 + cyclophosphamide 200 mg/kg or busulfan 16 mg/kg + cyclophosphamide 200 mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection." | 9.11 | Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. ( Balasubramanian, P; Chandy, M; Dennison, D; George, B; Krishnamoorthy, R; Mathews, V; Ramachandran, SV; Srivastava, A, 2005) |
| "We evaluated the incidence of GVHD, risk factors and the impact of graft composition on acute GVHD (aGVHD) in 92 children who underwent BMT for thalassemia following busulfan/cyclophosphamide (BUCY)-based conditioning regimens and GVHD prophylaxis with CSA/short-MTX and methylprednisolone." | 5.16 | Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. ( Adorno, G; Alfieri, C; Andreani, M; Daniele, N; De Angelis, G; Del Proposto, G; Gallucci, C; Gaziev, J; Isgrò, A; Lanti, A; Lucarelli, G; Marziali, M; Paciaroni, K; Roveda, A; Saltarelli, F; Simone, MD; Sodani, P; Testi, M, 2012) |
| "We prospectively studied the pharmacokinetics (PK) and clinical outcomes of intravenous busulfan (Bu) in 71 children with preexisting liver damage who underwent hematopoietic stem cell transplantation for thalassemia." | 5.14 | Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. ( Andreani, M; Bernardini, S; Casella, M; Federici, G; Formosa, A; Gaziev, J; Gravina, P; Isgrò, A; Lucarelli, G; Marziali, M; Mozzi, AF; Nguyen, L; Perrone Donnorso, M; Puozzo, C; Simone, MD; Sodani, P; Testi, M, 2010) |
| "In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600 mg/m2 + cyclophosphamide 200 mg/kg or busulfan 16 mg/kg + cyclophosphamide 200 mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection." | 5.11 | Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. ( Balasubramanian, P; Chandy, M; Dennison, D; George, B; Krishnamoorthy, R; Mathews, V; Ramachandran, SV; Srivastava, A, 2005) |
| " busulfan and post-transplant graft-versus-host disease (GVHD) prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil." | 3.96 | Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen. ( Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Iamsirirak, P; Jetsrisuparb, A; Lektrakul, Y; Meekaewkunchorn, A; Pakakasama, S; Pongphitcha, P; Rujkijyanont, P; Sanpakit, K; Sirachainan, N; Sirireung, S; Songdej, D; Sruamsiri, R; Surapolchai, P; Wahidiyat, PA, 2020) |
| " Conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (160 mg/kg) followed by cyclosporine and methotrexate as graft-versus-host disease prophylaxes." | 3.76 | Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. ( Ashouri, A; Babaie, MH; Ghavamzadeh, A; Iravani, M; Khatami, F; Tavakoli, E, 2010) |
| "Using nonmyeloablative, immunosuppressive, fludarabine (FLU)-based conditioning regimens, we have performed allogeneic peripheral blood stem cell transplants in 26 patients (8 with chronic myelogenous leukemia, 6 with acute myelogenous leukemia, 10 with acute lymphoblastic leukemia, 1 with myelodysplasia, and 1 with thalassemia major)." | 3.71 | Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. ( Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin." | 3.70 | Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin. ( Haghshenas, M; Khojasteh, HN; Ramzi, M; Zakerinia, M, 1999) |
| "Patients with class 3 thalassemia with high-risk features for adverse events after high-dose chemotherapy with hematopoietic stem cell transplantation (HSCT) are difficult to treat, tending to either suffer serious toxicity or fail to establish stable graft function." | 2.78 | Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. ( Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Pakakasama, S; Rujkijyanont, P; Sirachainan, N; Sirireung, S; Songdej, D; Srisala, S; Sruamsiri, R; Ungkanont, A, 2013) |
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| "Busulfan was quantitated using ultraviolet absorbance detection after derivatization and HPLC separation." | 1.32 | Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. ( Blazar, B; Bostrom, B; Bruns, A; Enockson, K; Johnson, A, 2003) |
| " Although busulfan is used frequently in children as part of a myeloablative regimen prior to bone marrow transplantation, pharmacokinetic data on intravenous busulfan in children are scarce." | 1.31 | Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. ( Ball, L; Bredius, R; Cremers, S; den Hartigh, J; Schoemaker, R; Twiss, I; Vermeij, P; Vossen, J, 2002) |
| "Busulfan (BU) is a widely used alkylating agent for antineoplastic therapy and marrow ablation in preparation for bone marrow transplantation (BMT)." | 1.30 | Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. ( Lai, WK; Law, LK; Li, CK; Pang, CP; Wong, R; Yuen, PM, 1998) |
| "The syndrome was characterised by sudden onset of circulatory shock and cardiac arrest." | 1.28 | Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. ( Angelucci, E; Baronciani, D; Cesaroni, P; Durazzi, SM; Galimberti, M; Giardini, C; Lucarelli, G; Mariotti, E; Muretto, P; Polchi, P, 1992) |
| " Both patients received an initial course of therapy, constantly of myleran at a dosage of 0." | 1.28 | Treatment of severe beta-thalassemia (patients) with myleran. ( Ao, ZH; Chen, SS; Huang, YW; Jia, PC; Jin, HQ; Liang, CC; Liu, DP; Liu, LJ; Wang, RX; Zha, DY, 1990) |
| " The results of analysis of sister chromatid exchange (SCE) showed no irreversible damage on chromosomal DNA of the patients at the dosage used (0." | 1.28 | [Further study on the treatment of severe beta-thalassemia with myleran]. ( Liang, Z, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (40.43) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 6 (12.77) | 29.6817 |
| 2010's | 8 (17.02) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Mehta, P | 1 |
| Kapoor, J | 1 |
| Singh, A | 1 |
| Yadav, N | 1 |
| Singh, R | 1 |
| Halder, R | 1 |
| Verma, M | 1 |
| Agrawal, N | 1 |
| Ahmed, R | 1 |
| Bhurani, D | 1 |
| Rossi, M | 1 |
| Szepetowski, S | 1 |
| Yakouben, K | 1 |
| Paillard, C | 1 |
| Sirvent, A | 1 |
| Castelle, M | 1 |
| Pegon, C | 1 |
| Piguet, C | 1 |
| Grain, A | 1 |
| Angoso, M | 1 |
| Robin, M | 1 |
| Dhedin, N | 1 |
| Pondarré, C | 1 |
| Dumesnil de Maricourt, C | 1 |
| Berceanu, A | 1 |
| Simon, P | 1 |
| Marcais, A | 1 |
| Poirée, M | 1 |
| Gandemer, V | 1 |
| Plantaz, D | 1 |
| Nguyen, S | 1 |
| Michel, G | 1 |
| Loundou, A | 1 |
| Dalle, JH | 1 |
| Thuret, I | 1 |
| Anurathapan, U | 3 |
| Hongeng, S | 3 |
| Pakakasama, S | 3 |
| Songdej, D | 3 |
| Sirachainan, N | 3 |
| Pongphitcha, P | 1 |
| Chuansumrit, A | 3 |
| Charoenkwan, P | 3 |
| Jetsrisuparb, A | 3 |
| Sanpakit, K | 2 |
| Rujkijyanont, P | 3 |
| Meekaewkunchorn, A | 2 |
| Lektrakul, Y | 1 |
| Iamsirirak, P | 1 |
| Surapolchai, P | 1 |
| Sirireung, S | 2 |
| Sruamsiri, R | 3 |
| Wahidiyat, PA | 1 |
| Andersson, BS | 3 |
| Ramprakash, S | 1 |
| Raghuram, CP | 1 |
| Marwah, P | 1 |
| Soni, R | 1 |
| Trivedi, D | 1 |
| Khalid, S | 1 |
| Yaqub, N | 1 |
| Itrat, F | 1 |
| Gilani, SK | 1 |
| Zahra, T | 1 |
| Dhanya, R | 1 |
| Agarwal, RK | 1 |
| Faulkner, L | 1 |
| Sheth, V | 1 |
| Grisariu, S | 1 |
| Avni, B | 1 |
| Stepensky, P | 1 |
| Ashkenazi, M | 1 |
| Shapira, MY | 1 |
| Or, R | 3 |
| Issaragrisil, S | 2 |
| Ungkanont, A | 2 |
| Srisala, S | 1 |
| Mekjaruskul, P | 1 |
| Pongtanakul, B | 1 |
| Iravani, M | 1 |
| Tavakoli, E | 1 |
| Babaie, MH | 1 |
| Ashouri, A | 1 |
| Khatami, F | 1 |
| Ghavamzadeh, A | 2 |
| Gaziev, J | 4 |
| Nguyen, L | 1 |
| Puozzo, C | 1 |
| Mozzi, AF | 1 |
| Casella, M | 1 |
| Perrone Donnorso, M | 1 |
| Gravina, P | 1 |
| Sodani, P | 3 |
| Marziali, M | 2 |
| Isgrò, A | 2 |
| Simone, MD | 2 |
| Andreani, M | 5 |
| Formosa, A | 1 |
| Testi, M | 2 |
| Federici, G | 1 |
| Bernardini, S | 1 |
| Lucarelli, G | 17 |
| Hamidieh, AA | 1 |
| Hamedani, R | 1 |
| Hadjibabaie, M | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Bertaina, A | 1 |
| Bernardo, ME | 1 |
| Mastronuzzi, A | 1 |
| La Nasa, G | 2 |
| Locatelli, F | 1 |
| Daniele, N | 1 |
| Gallucci, C | 1 |
| Adorno, G | 1 |
| Paciaroni, K | 1 |
| Lanti, A | 1 |
| Del Proposto, G | 1 |
| De Angelis, G | 1 |
| Roveda, A | 1 |
| Alfieri, C | 1 |
| Saltarelli, F | 1 |
| Bostrom, B | 1 |
| Enockson, K | 1 |
| Johnson, A | 1 |
| Bruns, A | 1 |
| Blazar, B | 1 |
| Zakrzewski, JL | 1 |
| Chandy, M | 1 |
| Balasubramanian, P | 1 |
| Ramachandran, SV | 1 |
| Mathews, V | 1 |
| George, B | 1 |
| Dennison, D | 1 |
| Krishnamoorthy, R | 1 |
| Srivastava, A | 1 |
| Polchi, P | 13 |
| Thomas, ED | 1 |
| Giardini, C | 7 |
| Galimberti, M | 11 |
| Baronciani, D | 9 |
| Angelucci, E | 8 |
| Erer, B | 1 |
| Tomasucci, M | 1 |
| Lai, WK | 1 |
| Pang, CP | 1 |
| Law, LK | 1 |
| Wong, R | 1 |
| Li, CK | 1 |
| Yuen, PM | 1 |
| Khojasteh, HN | 1 |
| Zakerinia, M | 1 |
| Ramzi, M | 1 |
| Haghshenas, M | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Gómez-Almaguer, D | 1 |
| Ruiz-Argüelles, A | 1 |
| González-Llano, O | 1 |
| Cantú, OG | 1 |
| Jaime-Pérez, JC | 1 |
| Cremers, S | 1 |
| Schoemaker, R | 1 |
| Bredius, R | 1 |
| den Hartigh, J | 1 |
| Ball, L | 1 |
| Twiss, I | 1 |
| Vermeij, P | 1 |
| Vossen, J | 1 |
| Mariotti, E | 1 |
| Cesaroni, P | 1 |
| Durazzi, SM | 4 |
| Muretto, P | 1 |
| Liu, DP | 1 |
| Liang, CC | 1 |
| Ao, ZH | 1 |
| Jia, PC | 1 |
| Chen, SS | 1 |
| Wang, RX | 1 |
| Liu, LJ | 1 |
| Jin, HQ | 1 |
| Zha, DY | 1 |
| Huang, YW | 1 |
| Liang, Z | 1 |
| Nicolini, G | 1 |
| Politi, P | 4 |
| Albertini, F | 2 |
| De Sanctis, V | 2 |
| Vullo, C | 2 |
| Bagni, B | 1 |
| Ruggiero, L | 1 |
| Filocamo, M | 2 |
| Bartolucci, M | 1 |
| Manenti, F | 3 |
| Barrett, AJ | 1 |
| Gale, RP | 1 |
| Sobocinski, A | 1 |
| Horowitz, M | 1 |
| Bortin, MM | 1 |
| Di Bartolomeo, P | 1 |
| Di Girolamo, G | 1 |
| Angrilli, F | 1 |
| Catinella, V | 1 |
| Ciancarelli, M | 1 |
| Dragani, A | 1 |
| D'Antonio, D | 1 |
| Palka, G | 1 |
| Guanciali-Franchi, P | 1 |
| Iacone, A | 1 |
| Hugh-Jones, K | 1 |
| Vellodi, A | 1 |
| Jones, ST | 1 |
| Hobbs, JR | 1 |
| Rogers, JR | 1 |
| Abdul-Ahad, A | 1 |
| Frappaz, D | 2 |
| Gluckman, E | 1 |
| Souillet, G | 1 |
| Maraninchi, D | 1 |
| Demeocq, F | 1 |
| Fischer, A | 1 |
| Lutz, P | 1 |
| Bergerat, JP | 1 |
| Hervé, P | 1 |
| Freycon, F | 2 |
| Naparstek, E | 1 |
| Aker, M | 1 |
| Cividalli, G | 2 |
| Engelhard, D | 1 |
| Brautbar, C | 2 |
| Weshler, Z | 1 |
| Weiss, L | 1 |
| Mumcuoglu, M | 1 |
| Rachmilewitz, EA | 1 |
| Centis, F | 2 |
| Agostinelli, F | 2 |
| Giorgi, C | 2 |
| Filippetti, A | 1 |
| Capriotti, L | 1 |
| Salvadori, P | 1 |
| Dardanelli, C | 1 |
| Barbanti, I | 1 |
| Rossi, MC | 1 |
| De Biagi, M | 1 |
| Izzi, T | 2 |
| Delfini, C | 3 |
| Manna, M | 2 |
| Lin, KH | 1 |
| Lee, CJ | 1 |
| Lin, KS | 1 |
| Feig, SA | 1 |
| Slavin, S | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Rachmilewitz, E | 1 |
| Richard, O | 1 |
| Galacteros, F | 1 |
| Bertheas, MF | 1 |
| Dutou, L | 1 |
| Bouteille, M | 1 |
| Vowels, MR | 1 |
| Berdoukas, V | 1 |
| Lam-Po-Tang, PR | 1 |
| Ford, D | 1 |
| Porcellini, A | 1 |
| Moretti, L | 1 |
| Manna, A | 1 |
| Sparaventi, G | 1 |
| Bernadou, A | 1 |
| Clauvel, JP | 1 |
| Antebi, L | 1 |
| Bilski-Pasquier, G | 1 |
1 review available for busulfan and Thalassemias
| Article | Year |
|---|---|
[Major beta-thalassemia and bone marrow allograft. Two cases and a study of the literature].
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Infant; Male; Postoperative Complic | 1987 |
5 trials available for busulfan and Thalassemias
| Article | Year |
|---|---|
Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; | 2013 |
Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
Topics: Adolescent; Adult; Base Sequence; Busulfan; Child; Child, Preschool; Disease-Free Survival; DNA Prim | 2010 |
Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antigens, CD34; Bone Marrow Transplantation; Bu | 2012 |
Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphami | 2005 |
Bone marrow transplantation with T-cell depleted allografts for the treatment of severe beta thalassemia major.
Topics: Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Cyclophosphamide; Graft Enhancement | 1989 |
41 other studies available for busulfan and Thalassemias
| Article | Year |
|---|---|
Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft vs Host | 2022 |
Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of Stem C
Topics: Busulfan; Chimerism; France; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; | 2023 |
Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thalassemia | 2020 |
Splenomegaly May Increase the Risk of Rejection in Low-Risk Matched Related Donor Transplant for Thalassemia, This Risk Can Be Partially Overcome by Additional Immunosuppression during Conditioning.
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; France; Germany; Graft vs Host Disease; Humans; Re | 2020 |
Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Huma | 2018 |
Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Sur | 2014 |
Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2010 |
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Female; Hem | 2010 |
Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 2003 |
Cyclosporin A-associated status epilepticus related to hematopoietic stem cell transplantation for thalassemia.
Topics: Anticonvulsants; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease Suscepti | 2003 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Allogeneic bone marrow transplantation for blood cell disorders.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Animals; Bone Marrow Transplantation; Busulfan; | 1982 |
Bone marrow transplantation in class 2 thalassemia patients.
Topics: Adolescent; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyc | 1993 |
Hemorrhagic cystitis after allogeneic bone marrow transplantation for thalassemia.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Child, Prescho | 1993 |
Routine analysis of plasma busulfan by gas chromatography-mass fragmentography.
Topics: Adolescent; Alkylating Agents; Busulfan; Child; Gas Chromatography-Mass Spectrometry; Humans; Sensit | 1998 |
Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antilymphocyte Serum; Bone Marrow Transplantati | 1999 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow- | 2001 |
Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Topics: Adolescent; Area Under Curve; Bayes Theorem; Busulfan; Child; Child, Preschool; Half-Life; Hematopoi | 2002 |
Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Busulfan; Cardiac Tamponade; Child; Child, P | 1992 |
Treatment of severe beta-thalassemia (patients) with myleran.
Topics: Busulfan; Child; DNA; Erythrocyte Count; Female; Fetal Hemoglobin; Globins; Humans; Leukocyte Count; | 1990 |
[Further study on the treatment of severe beta-thalassemia with myleran].
Topics: Busulfan; Child; Child, Preschool; Female; Genes; Globins; Humans; Male; Mutation; Sister Chromatid | 1991 |
Bone marrow transplantation in thalassemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1991 |
Endocrine function after bone marrow transplantation for thalassemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Endocrine System Disease | 1991 |
Gonadal function after allogenic bone marrow transplantation for thalassaemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Chorionic Gonadotropin; Cyclophosphamide; | 1991 |
CMV infections in thalassemia patients after BMT.
Topics: Adolescent; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1989 |
Bone marrow transplantation in thalassemia. The experience of Pesaro.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft | 1989 |
Bone marrow transplantation for thalassaemia--a preliminary report from the International Bone Marrow Transplant Registry.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Female; Graft vs Host | 1989 |
Bone marrow transplantation for thalassemia in Pescara.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Female; Graft vs Host Di | 1989 |
Bone marrow transplantation for thalassaemia: Westminster Children's Hospital and United Kingdom experience.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; England; Graft vs | 1989 |
Bone marrow transplantation (BMT) for thalassemia major (TM). The French experience.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; France; Graft Reje | 1989 |
Patterns of graft rejection after bone marrow transplant in thalassemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft | 1989 |
Liver iron stores before and after bone marrow transplantation for thalassemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Deferoxamine; Ferritins; Graft vs Ho | 1989 |
Immunologic recovery in thalassemic marrow graft recipients following high-dose busulfan and cyclophosphamide.
Topics: Antigens, Differentiation, T-Lymphocyte; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cy | 1988 |
Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.
Topics: Actuarial Analysis; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Com | 1985 |
Allogeneic marrow transplantation for thalassemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Ma | 1988 |
Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Infa | 1988 |
Bone marrow transplantation in thalassemia after busulphan and cyclophosphamide. Report on 88 cases.
Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosph | 1987 |
Bone-marrow transplantation for thalassaemia.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Graft vs Host Disease; Humans; Infant; Info | 1986 |
Marrow transplantation for thalassemia after treatment with busulfan and cyclophosphamide.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide | 1985 |
[Vaquez's diseas. Clinical and developmental study. Apropos of 144 cases].
Topics: Adult; Arteriosclerosis; Arteritis; Blood Sedimentation; Busulfan; Child; Erythrocyte Count; Female; | 1968 |